Gossamer Bio, Inc. (GOSS)
9.31
-0.57
(-5.77%)
USD |
NASDAQ |
Oct 09, 16:00
9.29
-0.02
(-0.21%)
After-Hours: 20:00
Gossamer Bio Cash from Operations (Quarterly) : -41.39M for June 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -41.39M |
| March 31, 2026 | -38.72M |
| December 31, 2025 | -48.31M |
| September 30, 2025 | -36.17M |
| June 30, 2025 | -47.06M |
| March 31, 2025 | -39.72M |
| December 31, 2024 | -35.48M |
| September 30, 2024 | -32.03M |
| June 30, 2024 | 116.35M |
| March 31, 2024 | -52.30M |
| December 31, 2023 | -33.42M |
| September 30, 2023 | -34.49M |
| June 30, 2023 | -38.25M |
| March 31, 2023 | -52.99M |
| December 31, 2022 | -47.73M |
| September 30, 2022 | -37.00M |
| June 30, 2022 | -48.82M |
| March 31, 2022 | -53.48M |
| Date | Value |
|---|---|
| December 31, 2021 | -40.51M |
| September 30, 2021 | -42.04M |
| June 30, 2021 | -47.45M |
| March 31, 2021 | -58.90M |
| December 31, 2020 | -36.74M |
| September 30, 2020 | -44.93M |
| June 30, 2020 | -42.40M |
| March 31, 2020 | -52.30M |
| December 31, 2019 | -44.14M |
| September 30, 2019 | -36.11M |
| June 30, 2019 | -36.81M |
| March 31, 2019 | -27.77M |
| December 31, 2018 | -25.02M |
| September 30, 2018 | |
| June 30, 2018 | |
| March 31, 2018 | -3.708M |
| December 31, 2017 | -5.721M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| United Therapeutics Corp. | 310.20M |
| Arbutus Biopharma Corp. | -5.952M |
| Kura Oncology, Inc. | -62.55M |
| ACADIA Pharmaceuticals, Inc. | 100.78M |
| Alnylam Pharmaceuticals, Inc. | 326.72M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 42.70M |
| Cash from Financing (Quarterly) | -1.181M |
| Free Cash Flow | -164.59M |
| Free Cash Flow Per Share (Quarterly) | -10.07 |
| Free Cash Flow to Equity (Quarterly) | 121.48M |
| Free Cash Flow to Firm (Quarterly) | -38.68M |
| Free Cash Flow Yield | -556.0% |